γ-Cyclodextrin-based Metal-Organic Framework Embedded with Graphene Quantum Dots and Modified with PEGMA via SI-ATRP for Anticancer Drug Delivery and Therapy
The γ-cyclodextrin-based metal-organic framework (γ-CD-MOF) composite was designed and prepared toward targeted anticancer drug delivery and cancer therapy. Large amounts of graphene quantum dots (GQDs) were embedded in the γ-CD-MOF matrix (denoted as GQDs@γ-CD-MOF) to endow γ-CD-MOF with strong fluorescence, which was then modified by pH responsive poly(ethyleneglycol)dimethacrylate (PEGMA) through surface initiated atom transfer radical polymerization (SI-ATRP) to fabricate the PEGMA@GQDs@γ-CD-MOF composite. Then, the cancer cell-targeted probe was ob-tained by immobilizing AS1411 aptamer over it (denoted as AS1411@PEGMA@GQDs@γ-CD-MOF) and exhibit pH-responsive release function and excellent targeting ability. Large amounts of antitumor drug, doxorubicin hydrochlo-ride (DOX), could be encapsulated within this composite due to the chemical-rich func-tionality, and the resultant pH-responsive DOX delivery system (denoted as DOX/AS1411@PEGMA@GQDs@γ-CD-MOF) displayed a higher DOX loading of 89.1% with sustained release than the pristine γ-CD-MOF and GQDs@γ-CD-MOF. The targeting specificity investigation revealed that this DOX delivery system was effectively internalized via the receptor mediated endocytosis with high selectivity. The in vivo anti-tumor study with tumor-bearing mice illustrated that the tumor growth can be effectively suppressed and partially ablated with negligible side effects after treatments. Therefore, the proposed AS1411@PEGMA@GQDs@γ-CD-MOF composite is promising for effec-tive DOX delivery and tumor growth inhibitation both in vitro and in vivo, showing a great potential for anticancer therapy.